Complement Inhibitor Therapy for Myasthenia Gravis

by Khaled Albazli, Henry J. Kaminski, James F. Howard
Published 2020-06-01

Consistent improvement with eculizumab across muscle groups in myasthenia gravis

by Renato Mantegazza, Fanny L. O'Brien, Marcus Yountz, James F. Howard Jr, for the REGAIN study group
Published 2020-08-01

Long‐term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses

by James F. Howard Jr, Chafic Karam, Marcus Yountz, Fanny L. O’Brien, Tahseen Mozaffar, for the REGAIN Study Group
Published 2021-07-01

Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension Study

by Richard J. Nowak, Srikanth Muppidi, Said R. Beydoun, Fanny L. O'Brien, Marcus Yountz, James F. Howard
Published 2020-11-01

Clinical outcome measures following plasma exchange for MG exacerbation

by Shruti M. Raja, James F. Howard Jr, Vern C. Juel, Janice M. Massey, Manisha Chopra, Jeffrey T. Guptill
Published 2019-10-01

Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study

by Saiju Jacob, Hiroyuki Murai, Kimiaki Utsugisawa, Richard J. Nowak, Heinz Wiendl, Kenji P. Fujita, Fanny O’Brien, James F. Howard
Published 2020-04-01

Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North America

by Joel Oger, Joshua D Green, Bryan J Traynor, Richard J Barohn, Michael Benatar, Emanuela Bartoccion, Derrick Blackmore, Manisha Chopra, Andrea Corse, Mazen M Dimachkie, Amelia Evoli, Julaine Florence, Miriam Freimer, James F Howard, Theresa Jiwa, Henry J Kaminski, John T Kissel, Wilma J Koopman, Bernadette Lipscomb, Michelanglo Maestri, Mariapaola Marino, Janice M Massey, April McVey, Michelle M Mezei, Michael W Nicolle, Robert M Pascuzzi, Mamatha Pasnoor, Alan Pestronk, Carlo Provenzano, Roberta Ricciardi, David P Richman, Julie Rowin, Donald B Sanders, Zaeem Siddiqi, Aimee Soloway, Gil I Wolfe, Charlie Wulf, Daniel B Drachman
Published 2020-09-01

A checklist for clinical trials in rare disease: obstacles and anticipatory actions—lessons learned from the FOR-DMD trial

by Rebecca A. Crow, Kimberly A. Hart, Michael P. McDermott, Rabi Tawil, William B. Martens, Barbara E. Herr, Elaine McColl, Jennifer Wilkinson, Janbernd Kirschner, Wendy M. King, Michele Eagle, Mary W. Brown, Deborah Hirtz, Hanns Lochmuller, Volker Straub, Emma Ciafaloni, Perry B. Shieh, Stefan Spinty, Anne-Marie Childs, Adnan Y. Manzur, Lucia Morandi, Russell J. Butterfield, Iain Horrocks, Helen Roper, Kevin M. Flanigan, Nancy L. Kuntz, Jean K. Mah, Leslie Morrison, Basil T. Darras, Maja von der Hagen, Ulrike Schara, Ekkehard Wilichowski, Tiziana Mongini, Craig M. McDonald, Giuseppe Vita, Richard J. Barohn, Richard S. Finkel, Matthew Wicklund, Hugh J. McMillan, Imelda Hughes, Elena Pegoraro, W. Bryan Burnette, James F. Howard, Mathula Thangarajh, Craig Campbell, Robert C. Griggs, Kate Bushby, Michela Guglieri
Published 2018-05-01